1403POpen-label multicenter randomized phase II study of docetaxel plus bevacizumab or pemetrexed plus bevacizumab for elderly (≥75 years old) patients (pts) with previously untreated advanced non-squamous non-small cell lung cancer (NSCLC): TORG1323. (23rd October 2018) - Honda, T; Kouzuki, T; Tsunezuka, Y; Seki, N; Shibayama, T; Okimoto, T; Taniguchi, H; Takeda, Y; Hata, N; Sugimoto, K; Takahashi, N; Sakai, K; et al.